Non-Small Cell Lung Cancer (NSCLC)

Joshua K. Sabari, MD, reviews the primary results from the MARIPOSA study presented at ESMO 2023 looking at amivantamab plus lazertinib in EGFR-mutated advanced NSCLC.

Data from the phase 1/2 TRIDENT-1 trial support the FDA approval of repotrectinib for those with ROS1-positive advanced or metastatic non–small cell lung cancer.

Adagrasib, which now has a positive CHMP opinion, was previously examined as part of the phase 1/2 KRYSTAL-1 study.

Sai-Hong Ou, MD, PhD, discusses the rapidly evolving landscape of first-line therapy for sensitizing EGFR mutant non-small cell lung cancer, including potential combination therapies and the introduction of new treatment options, such as antibody drug conjugates.

Dr Sai-Hong Ou and Dr Janellen Smith discuss the case of a 59-year-old patient with non-small cell lung cancer and an EGFR mutation who experienced severe diarrhea and acne form rash while on osimertinib, providing insights into managing these treatment-related side effects.

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C, discussed how to best mitigate adverse effects in patients with non–small cell lung cancer.

A medical oncologist discusses data from the LIBRETTO-431 clinical trial looking at first-line selpercatinib vs chemotherapy and pembrolizumab in RET fusion–positive NSCLC.

Sandip P. Patel, MD, reviews recent data from the PAPILLON study investigating amivantamab plus chemotherapy in the first line for patients with EGFR exon 20 insertion–mutated advanced NSCLC.

Dr Sai-Hong Ou highlights the significance of next-generation sequencing for detecting EGFR mutations in patients with non-small cell lung cancer and the potential for adjuvant testing regardless of disease stage.

In this program, Sai-Hong Ou, MD, PhD, discusses biomarker testing for precision medicine in non-small cell lung cancer, emphasizing the importance of both tissue and blood-based genotyping, and the need for a complementary approach due to potential limitations in detecting targetable mutations.

Results from the phase 2 THIO-101 trial demonstrate disease control in all 19 patients with non–small cell lung cancer who received second-line THIO plus cemiplimab.

Investigators of the phase 3 KEYNOTE-671 trial identify no new safety signals with pembrolizumab plus chemotherapy in those with early-stage non–small cell lung cancer.

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C, emphasize the importance of patient education, discussing how understanding the biological reasons behind treatments for EGFR-mutated non-small cell lung cancer and their side effects can lead to better outcomes, and highlighting the need for collaborative care and clear communication.

Data from the phase 3 KEYNOTE-091 trial supported the European Commission’s approval of pembrolizumab as an adjuvant treatment for adults with non–small cell lung cancer at high risk of recurrence following complete resection and platinum-based chemotherapy.

Amivantamab plus chemotherapy may be the new standard of care for patients with EGFR-mutated advanced non–small cell lung cancer that has progressed following osimertinib, according to Antonio Passaro, MD, PhD.

Objective response rate appears to be higher with datopotamab deruxtecan compared with docetaxel among patients with advanced or metastatic non–small cell lung cancer in the phase 3 TROPION-Lung01 study.

Amivantamab plus lazertinib may represent a new standard of care in those with EGFR-mutated advanced non–small cell lung cancer, according to Byoung Chul Cho, MD, PhD.

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C, discuss the importance of early dermatological consultations and multidisciplinary education for managing infusion-related adverse events like rashes from amivantamab, emphasizing the benefits of a well-coordinated team and the value of experience in responding to reactions.

Kristen Neumann, DNP, FNP-C, emphasizes the efficacy of the drug amivantamab for patients with EGFR exon 20 mutations, explaining the challenges of unique skin rashes, but highlighting the importance of teamwork in effectively managing and treating these adverse skin effects.

Amivantimab produces superior progression-free survival in EGFR exon 20 insertion–positive non–small-cell lung cancer.

Patients with RET fusion–positive non–small cell lung cancer experienced improved progression-free survival with first-line selpercatinib.

Alectinib improves disease-free survival in patients with ALK-positive non–small-cell lung cancer.

Central nervous system progression was reduced with osimertinib plus chemotherapy for patients with EGFR-mutated non-small cell lung cancer plus CNS metastases.

Neoadjuvant nivolumab combination followed by surgery and adjuvant nivolumab show an improvement in event-free survival for patients with previously untreated resectable stage II to IIIB non-small cell lung cancer.

Results from the phase 2 PERLA trial showed an improved objective response and overall survival in treatment with dostarlimab plus chemotherapy in patients with treatment-naïve, nonsquamous non–small cell lung cancer.

Data from the phase 2 KRYSTAL-7 study support a phase 3 trial assessing concurrent adagrasib plus pembrolizumab compared with pembrolizumab alone in treatment-naïve KRAS G12C-mutated non–small cell lung cancer.

Data from a phase 1a/1b trial support additional research on dual TIGIT/PD-L1 inhibition in patients with advanced solid tumors.

The FDA companion diagnostic designation for the FoundationOne CDx and FoundationOne Liquid CDx may improve access to treatment with encorafenib plus binimetinib for those with BRAF V600E-mutated non–small cell lung cancer.

Those with resectable non–small cell lung cancer can now receive neoadjuvant treatment with pembrolizumab and chemotherapy followed by adjuvant pembrolizumab after approval by the FDA.

Results from the phase 3 FLAURA2 trial allowed for the combination of osimertinib plus chemotherapy to be submitted for priority review.